{"id":15745,"date":"2023-03-12T19:22:19","date_gmt":"2023-03-12T19:22:19","guid":{"rendered":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/"},"modified":"2023-07-06T19:53:20","modified_gmt":"2023-07-06T19:53:20","slug":"la-prima-valutazione-della-sindrome-di-rett-eine-moegliche-hoffnung-per-i-pazienti-con-la-sindrome-di-mecp2-genduplikation","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/it\/la-prima-valutazione-della-sindrome-di-rett-eine-moegliche-hoffnung-per-i-pazienti-con-la-sindrome-di-mecp2-genduplikation\/","title":{"rendered":"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom?"},"content":{"rendered":"<p>10. M\u00e4rz 2023 \u00e8 un dato molto importante per la comunit\u00e0 delle malattie gravi.<\/p>\n\n\n\n<p>La trofinetide \u00e8 stata approvata dall'FDA per il trattamento dei pazienti con <a href=\"#rett\" target=\"_blank\" rel=\"noreferrer noopener\">Sindrome di Rett<\/a> ed \u00e8 quindi la prima terapia per il sindrome di Rett. Il farmaco, che viene commercializzato con il nome Daybue\u2122, \u00e8 disponibile da fine aprile 2023 negli Stati Uniti per pazienti di et\u00e0 inferiore ai 2 anni.<\/p>\n\n\n\n<p>La trofinetide \u00e8 un tripeptide derivato da una proteina chiamata insulin\u00e4hnlicher Wachstumsfaktor 1 (IGF-1). Es kann m\u00fcndlich verabreicht werden. Es wird angenommen, dass dieses Medikament die Entz\u00fcndung reduziert und die Kommunikation zwischen den Neuronen im Gehirn verbessert, die bei Menschen mit Rett-Syndrom gest\u00f6rt sind. Gli studi clinici di fase III hanno dimostrato che la Trofinetide ha ridotto i sintomi del sindrome di Rett, tra cui la comunicazione sociale, il senso di colpa e la capacit\u00e0 di manipolazione.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-background wp-element-button\" href=\"\" style=\"border-radius:12px;background-color:#f7a13f\" target=\"_blank\" rel=\"noreferrer noopener\">Per saperne di pi\u00f9 sull'Acadia<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>La malattia genetica dei MECP2-Duplikationssyndroms (MDS) si distingue da quella dei MECP2-Duplikationssyndroms (MDS). <a href=\"#rett\">Sindromi Rett<\/a>Tuttavia, in entrambi i casi \u00e8 presente una mutazione nel gene MECP2. La sindrome di Rett colpisce soprattutto i ragazzi e le ragazze e presenta un basso livello di proteina MeCP2, mentre la MDS, che viene diagnosticata soprattutto nei giovani, comporta livelli pi\u00f9 elevati di proteina. Interessanterweise sowohl beim Rett-Syndrom als auch beim MDS die Entwicklung und Funktion des Gehirns gest\u00f6rt, was zu \u00e4hnlichen Symptomen wie geistiger Behinderung, Koordinationsproblemen und Krampfanf\u00e4llen f\u00fchrt.<\/p>\n\n\n\n<p>Daher tragen die wissenschaftlichen Fortschritte beim Rett-Syndrom dazu bei, das Wissen \u00fcber MDS zu erweitern. La Zulassung von Daybue\u2122 offre la possibilit\u00e0 di effettuare ulteriori ricerche sull'utilizzo della trofinetide nei pazienti con sindrome MECP2-Genduplikation.<\/p>\n\n\n\n<p>Il conflitto con la sindrome MECP2-Genduplikation non \u00e8 ancora finito. Tragen Sie dazu bei, die Forschung an einer Behandlung f\u00fcr MDS voranzutreiben, indem Sie spenden, das Bewusstsein f\u00fcr das Syndrom sch\u00e4rfen und sich unseren Aktionen anschlie\u00dfen.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-background wp-element-button\" href=\"https:\/\/dupmecp2.eu\/it\/become-a-member\/?lang=en\" style=\"border-radius:12px;background-color:#f7a13f\">Impegnatevi!<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Der 10. M\u00e4rz 2023 ist ein sehr wichtiges Datum f\u00fcr die Gemeinschaft der seltenen Krankheiten. Trofinetide wurde von der FDA f\u00fcr die Behandlung von Patienten mit Rett-Syndrom zugelassen und ist [&hellip;]<\/p>","protected":false},"author":1,"featured_media":15705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57],"tags":[],"class_list":["post-15745","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aktualitat"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom? - DupMECP2<\/title>\n<meta name=\"description\" content=\"Trofinetide wurde von der FDA f\u00fcr die Behandlung von Patienten mit Rett-Syndrom zugelassen. Die Zulassung von Daybue\u2122 \u00f6ffnet die T\u00fcr f\u00fcr weitere Forschungen zum Einsatz von Trofinetide bei Patienten mit MECP2-Genduplikation Syndrom.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/it\/la-prima-valutazione-della-sindrome-di-rett-eine-moegliche-hoffnung-per-i-pazienti-con-la-sindrome-di-mecp2-genduplikation\/?lang=de\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom? - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Trofinetide wurde von der FDA f\u00fcr die Behandlung von Patienten mit Rett-Syndrom zugelassen. Die Zulassung von Daybue\u2122 \u00f6ffnet die T\u00fcr f\u00fcr weitere Forschungen zum Einsatz von Trofinetide bei Patienten mit MECP2-Genduplikation Syndrom.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/it\/la-prima-valutazione-della-sindrome-di-rett-eine-moegliche-hoffnung-per-i-pazienti-con-la-sindrome-di-mecp2-genduplikation\/?lang=de\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-12T19:22:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-06T19:53:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom?\",\"datePublished\":\"2023-03-12T19:22:19+00:00\",\"dateModified\":\"2023-07-06T19:53:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de\"},\"wordCount\":333,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"articleSection\":[\"Aktualit\u00e4t\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de\",\"url\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de\",\"name\":\"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom? - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"datePublished\":\"2023-03-12T19:22:19+00:00\",\"dateModified\":\"2023-07-06T19:53:20+00:00\",\"description\":\"Trofinetide wurde von der FDA f\u00fcr die Behandlung von Patienten mit Rett-Syndrom zugelassen. Die Zulassung von Daybue\u2122 \u00f6ffnet die T\u00fcr f\u00fcr weitere Forschungen zum Einsatz von Trofinetide bei Patienten mit MECP2-Genduplikation Syndrom.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aktualit\u00e4t\",\"item\":\"https:\/\/dupmecp2.eu\/category\/aktualitat\/?lang=de\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/it\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom? - DupMECP2","description":"La trofinetide \u00e8 stata approvata dalla FDA per il trattamento di pazienti con sindrome di Rett. La valutazione di Daybue\u2122 apre la strada a ulteriori ricerche sull'uso della trofinetide nei pazienti con sindrome di MECP2-Genduplikation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/it\/la-prima-valutazione-della-sindrome-di-rett-eine-moegliche-hoffnung-per-i-pazienti-con-la-sindrome-di-mecp2-genduplikation\/?lang=de","og_locale":"it_IT","og_type":"article","og_title":"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom? - DupMECP2","og_description":"Trofinetide wurde von der FDA f\u00fcr die Behandlung von Patienten mit Rett-Syndrom zugelassen. Die Zulassung von Daybue\u2122 \u00f6ffnet die T\u00fcr f\u00fcr weitere Forschungen zum Einsatz von Trofinetide bei Patienten mit MECP2-Genduplikation Syndrom.","og_url":"https:\/\/dupmecp2.eu\/it\/la-prima-valutazione-della-sindrome-di-rett-eine-moegliche-hoffnung-per-i-pazienti-con-la-sindrome-di-mecp2-genduplikation\/?lang=de","og_site_name":"DupMECP2","article_published_time":"2023-03-12T19:22:19+00:00","article_modified_time":"2023-07-06T19:53:20+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Caroline","Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom?","datePublished":"2023-03-12T19:22:19+00:00","dateModified":"2023-07-06T19:53:20+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de"},"wordCount":333,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","articleSection":["Aktualit\u00e4t"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de","url":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de","name":"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom? - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","datePublished":"2023-03-12T19:22:19+00:00","dateModified":"2023-07-06T19:53:20+00:00","description":"La trofinetide \u00e8 stata approvata dalla FDA per il trattamento di pazienti con sindrome di Rett. La valutazione di Daybue\u2122 apre la strada a ulteriori ricerche sull'uso della trofinetide nei pazienti con sindrome di MECP2-Genduplikation.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/erste-zugelassene-behandlung-fuer-das-rett-syndrom-eine-moegliche-hoffnung-fuer-patienten-mit-mecp2-genduplikation-syndrom\/?lang=de#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Aktualit\u00e4t","item":"https:\/\/dupmecp2.eu\/category\/aktualitat\/?lang=de"},{"@type":"ListItem","position":3,"name":"Erste zugelassene Behandlung f\u00fcr das Rett-Syndrom: eine m\u00f6gliche Hoffnung f\u00fcr Patienten mit MECP2-Genduplikation Syndrom?"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/it\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/posts\/15745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/comments?post=15745"}],"version-history":[{"count":0,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/posts\/15745\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/media\/15705"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/media?parent=15745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/categories?post=15745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/tags?post=15745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}